Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Opens in a new tab or window Recently approved treatments for generalized myasthenia gravis (gMG), including ... acetylcholine receptor (AChR) antibody-positive gMG. The drugs carry a boxed ...

The prospective study included 62 patients with generalized myasthenia gravis who were positive for AChR-Ab. Researchers measured AChR-Ab titers, the Myasthenia Gravis Foundation of America ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular ...

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG ... antibody-positive. UCB also notes that unlike monoclonal ...